Durvalumab-Platinum Regimen for Muscle-Invasive Bladder Cancer Recurrence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet medical need for additional treatment options to improve survival and reduce recurrence rates in patients with muscle-invasive bladder cancer, as current treatments like cisplatin-based neoadjuvant chemotherapy and radical cystectomy still result in high recurrence rates and unclear benefits from adjuvant therapies.
Innovation Solution
Administering durvalumab, an anti-PD-L1 antibody, in combination with platinum-based chemotherapy before and after radical cystectomy, specifically following a neoadjuvant and adjuvant schedule, to enhance clinical response and survival outcomes in muscle-invasive bladder cancer patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cisplatin-based neoadjuvant chemotherapy and radical cystectomy are used as standard treatment, then the treatment protocol is well-established and relatively simple, but recurrence rates remain high and survival outcomes are limited
Solution Approach 1:
The patent combines durvalumab immunotherapy with cisplatin-based neoadjuvant chemotherapy and adjuvant therapy, creating a multi-modal treatment approach. This merging of different therapeutic mechanisms (immunotherapy + chemotherapy) aims to achieve synergistic effects that reduce recurrence rates more effectively than either treatment alone, directly addressing the limitation of high recurrence with standard therapy.
Solution Approach 2:
The patent implements neoadjuvant durvalumab chemotherapy before radical cystectomy to prepare and reduce tumor burden in advance. This preliminary action of administering immunotherapy prior to surgery enhances the effectiveness of subsequent treatments and aims to improve pathological complete response rates, thereby reducing recurrence risk before the disease can progress.
2Reliability
If adjuvant chemotherapy is administered after radical cystectomy, then post-surgical treatment coverage is improved, but the benefit to overall survival remains unclear and treatment duration increases
Solution Approach 1:
The patent employs risk-stratified adjuvant durvalumab therapy based on pathological response to neoadjuvant treatment. Patients are assessed for pathological complete response or residual disease, and adjuvant therapy is tailored accordingly. This feedback-driven approach optimizes treatment duration and intensity based on individual patient response, aiming to maximize survival benefit while avoiding unnecessary prolonged treatment in patients who achieve complete response.
Solution Approach 2:
The patent changes the treatment parameter from fixed-duration adjuvant chemotherapy to risk-adapted durvalumab therapy. By modifying the treatment approach based on pathological assessment (complete response vs. residual disease), the protocol adjusts therapy intensity and duration to match actual patient needs, potentially improving survival outcomes while reducing unnecessary treatment time for low-risk patients.
3Reliability
If platinum-based chemotherapy alone is used, then the treatment approach is straightforward and cost-effective, but clinical response and survival outcomes are insufficient
Solution Approach 1:
The patent merges durvalumab immunotherapy with platinum-based chemotherapy in a neoadjuvant setting, combining two different mechanisms of action (immune checkpoint inhibition + cytotoxic chemotherapy). This combination aims to achieve higher pathological complete response rates and improved survival outcomes compared to chemotherapy alone, directly addressing the insufficiency of single-modality treatment.
Solution Approach 2:
The patent uses durvalumab as an intermediary that enhances the effectiveness of platinum-based chemotherapy. By blocking PD-L1, durvalumab prevents tumor-mediated immune suppression and potentiates the anti-tumor effects of chemotherapy, creating a synergistic relationship where the immunotherapy mediator amplifies the impact of the chemotherapy on clinical response and survival.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy with durvalumab and platinum-based chemotherapy significantly improves event-free survival, overall survival, and pathological complete response rates in muscle-invasive bladder cancer patients, reducing recurrence and enhancing long-term prognosis.
Implementation Method 1
Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin (Ig) G1 kappa (IgG1κ) subclass that inhibits binding of PD-L1 (B7 homolog 1 [B7-H1], cluster of differentiation [CD]274) to PD-1 (CD279) and CD80 (B7-1). Nonclinical and clinical studies have indicated that blockade of the immune checkpoints PD-1/PD-L1 can have a positive effect on antitumor activity.
Data Source
AI summary
The disclosure relates to methods for treating patients with muscle-invasive bladder cancer using durvalumab and platinum-based chemotherapy. The present disclosure also relates to combination therapies comprising durvalumab and platinum-based chemotherapy for the treatment of patients with muscle invasive bladder cancer. The present disclosure further relates to the use of combination therapies comprising durvalumab and platinum-based chemotherapy for the manufacture of a medicament for treating patients with muscle invasive bladder cancer.